Community mental health care, monthly injectable olanzapine and pritelivir approval.
Mental health
WHO calls for community-based mental health care
Ahead of World Mental Health Day, WHO released a practical guide to help countries move from prolonged psychiatric institutional care towards person-centred community services. It emphasises that successful transitions require housing, healthcare, social support and participation by people with lived experience—not simply discharge from hospital.
Why it matters: Offers actionable priorities for mental-health service leaders, especially around continuity of care, patient rights and community support.
Teva announces FDA approval of monthly injectable olanzapine
Teva announced US FDA approval of Weltruza, a once-monthly subcutaneous olanzapine formulation for adults with schizophrenia. According to the company, it requires no loading doses, oral supplementation or post-injection monitoring; weight gain and metabolic changes remain important safety considerations.
Why it matters: Adds a formulation option relevant to treatment adherence and psychiatric service delivery, while preserving the need for ongoing clinical and metabolic monitoring.
FDA approves pritelivir for difficult-to-treat herpes infections
The FDA’s approval list records Hovilpri, containing pritelivir, as approved for immunocompromised adults with mucocutaneous herpes simplex lesions that have not responded to other therapies. The approval provides a new treatment option for a specifically defined population, rather than a general treatment for all herpes infections.
Why it matters: A relevant development for infectious-disease, transplant and oncology teams managing persistent infections in vulnerable patients.
Editorial summaries for general information only; not medical advice. Research findings and company announcements should be read in their original context.